ARTA
YMAB

A.R.T. Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

A.R.T. Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,482
Closed -$203K – 1018
2019
Q4 		$203K Buy
+6,482
New +$192K 0.01% 1153

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

A.R.T. Advisors's YMAB Position: Q1 2020 in Review

A.R.T. Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q1 2020, closing a stake of 6,482 shares — an estimated $203K sold.

A.R.T. Advisors first reported a position in YMAB in Q4 2019 and held it in 1 quarter. The position peaked at $203K in Q4 2019. 80 funds tracked by Wall St. Rank hold YMAB as of Q1 2020.

  • A.R.T. Advisors reported no remaining Y-mAbs Therapeutics position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 6,482 Y-mAbs Therapeutics shares in Q1 2020, an estimated $203K.
  • A.R.T. Advisors first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 1 quarter.
  • A.R.T. Advisors's Y-mAbs Therapeutics position peaked at $203K in Q4 2019.
  • 80 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.